Compare Organon & Co. Common Stock (OGN) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs 22nd Century Group Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: Organon & Co. Common Stock is far larger — about 7605.8× 22nd Century Group Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| OGN | XXII | |
|---|---|---|
Market Cap | $3.62B | $475.95K |
Volume | 2,892,999 | 78,911 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $483.00 |
52-Week Low | $5.70 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $11.04B | -$3.83M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
